$4.38
9.23%
Nasdaq, Oct 01, 01:15 pm EDT. Market open.
ISIN
US00688A1060
Symbol
ADIL

Adial Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation

Adial Pharmaceuticals, Inc. Classifications & Recommendation

Buy
80%
Hold
20%

Adial Pharmaceuticals, Inc. Price Target

Target Price $8.16
Price $4.01
Potential
Number of Estimates 5
5 Analysts have issued a price target Adial Pharmaceuticals, Inc. 2027 . The average Adial Pharmaceuticals, Inc. target price is $8.16. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 8 Analysts recommend Adial Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Adial Pharmaceuticals, Inc. stock has an average upside potential 2027 of . Most analysts recommend the Adial Pharmaceuticals, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ -11.93 -4.01
82.46% 66.39%
P/E negative

6 Analysts have issued a Adial Pharmaceuticals, Inc. forecast for earnings per share. The average Adial Pharmaceuticals, Inc. EPS is

$-4.01
unlock
. This is
67.92% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-1.10 91.20%
unlock
, the lowest is
$-6.95 44.40%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-11.93 82.46%
2026
$-4.01 66.39%
unlock
2027
$-1.26 68.58%
unlock
2028
$-1.21 3.97%
unlock
2029
$-1.92 58.68%
unlock
2030
$0.43 122.40%
unlock
2031
$1.50 248.84%
unlock
2032
$4.15 176.67%
unlock
2033
$6.19 49.16%
unlock

P/E ratio

Current -0.32 26.35%
2026
-1.00 211.72%
unlock
2027
-3.18 218.00%
unlock
2028
-3.32 4.40%
unlock

Current Adial Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Alliance Global Partners
Locked
➜
Locked
Locked Aug 03 2026
LUCID CAPITAL MARKETS
Locked
➜
Locked
Locked Jun 15 2026
Maxim Group
Locked
➜
Locked
Locked Sep 30 2025
Rodman & Renshaw
Locked
➜
Locked
Locked Nov 14 2024
Analyst Rating Date
Locked
Alliance Global Partners:
Locked
➜
Locked
Aug 03 2026
Locked
LUCID CAPITAL MARKETS:
Locked
➜
Locked
Jun 15 2026
Locked
Maxim Group:
Locked
➜
Locked
Sep 30 2025
Locked
Rodman & Renshaw:
Locked
➜
Locked
Nov 14 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today